Upgrade Alert for Infinity Pharmaceuticals (INFI)
Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded from Underperform to Neutral at Wedbush today. The stock closed yesterday at $1.36 on volume of 19.7 million shares, above average daily volume of 504,000.
Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
In the past 52 weeks, shares of Infinity Pharmaceuticals have traded between a low of $4.38 and a high of $50.51 and closed yesterday at $1.36, which is -69% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.6% while the 200-day MA has slid 1.1%.
Infinity Pharmaceuticals (NASDAQ:INFI) has potential upside of 1,076.5% based on a current price of $1.36 and analysts' consensus price target of $16.00. Infinity Pharmaceuticals shares should first meet resistance at the 50-day moving average (MA) of $6.00 and find additional resistance at the 200-day MA of $7.60.
SmarTrend is monitoring the recent change of momentum in Infinity Pharmaceuticals. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Infinity Pharmaceuticals in search of a potential trend change.
Keywords: analyst upgrades/downgrades infinity pharmaceuticals